← Back to Clinical Trials
Recruiting NCT06891131

NCT06891131 Implementation of an Empiric Transfusion Bundle for Out of Hospital Patients With Haemorrhagic Shock

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06891131
Status Recruiting
Phase
Sponsor Medical University of Graz
Condition Haemorrhagic Shock
Study Type OBSERVATIONAL
Enrollment 10 participants
Start Date 2025-06-01
Primary Completion 2027-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 10 participants in total. It began in 2025-06-01 with a primary completion date of 2027-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators will evaluate the implementation of a treatment bundle (Fibrinogen, Plasma and Tranexamic Acid)

Eligibility Criteria

Inclusion Criteria: * aged, or believed to be aged * 18 years or above * confirmed or suspected life-threatening bleeding from trauma (i.e. signs of inadequate perfusion of tissues, tachycardia, hypotension, suspected blood loss) * need for volume replacement therapy. Exclusion Criteria: * patient with known recent history of thromboembolic events within the last 6 months * known or suspected pregnancy at presentation * patient with known refusal of a participation in this clinical trial.

Contact & Investigator

Central Contact

Gabriel Honnef, MD, PhD

✉ gabriel.honnef@medunigraz.at

📞 +436509160890

Principal Investigator

Gabriel Honnef, MD, PhD

PRINCIPAL INVESTIGATOR

Medical University of Graz, Department of Anaesthesiology

Frequently Asked Questions

Who can join the NCT06891131 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Haemorrhagic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06891131 currently recruiting?

Yes, NCT06891131 is actively recruiting participants. Contact the research team at gabriel.honnef@medunigraz.at for enrollment information.

Where is the NCT06891131 trial being conducted?

This trial is being conducted at Graz, Austria.

Who is sponsoring the NCT06891131 clinical trial?

NCT06891131 is sponsored by Medical University of Graz. The principal investigator is Gabriel Honnef, MD, PhD at Medical University of Graz, Department of Anaesthesiology. The trial plans to enroll 10 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology